#USA #Seattle #SeptiCyte RAPID #Immunexpress #sepsis

Immunexpress Confirms SeptiCyte RAPID® Aids in Identifying Septic Patients

Immunexpress, a pioneering molecular diagnostics company, has recently announced the publication of a study that underscores the utility of their product, SeptiCyte RAPID®. The research highlights the tool's ability to identify septic patients who are most likely to have positive blood cultures, thus streamlining the clinical approach to sepsis management. This study, titled "Likelihood of Blood Culture Positivity Using SeptiCyte RAPID," showcases findings from a multi-center analysis involving over 500 critically ill and acutely ill patients from regions including North America, Europe, and sub-Saharan Africa.

Key Findings of the Study

The study's outcomes confirm that higher SeptiScores are closely linked with positive blood culture results. Specifically, more than 90% of patients with positive cultures fell into the highest SeptiScore bands, while no positive cases were found among those in the lowest score range. This distinct categorization enables healthcare providers to identify patients at low risk for sepsis effectively.

Additionally, the diagnostic capability of SeptiCyte RAPID is reflected in its impressive AUC (Area Under the Curve) score of 0.91, showcasing the test's precision in distinguishing between blood culture-positive sepsis cases and non-infectious systemic inflammation. Notably, the binary cut-point analysis indicated that the test achieved 100% sensitivity at lower SeptiScores and 100% specificity at higher scores—further emphasizing its potential clinical significance as an early risk assessment instrument.

Dr. Maik von der Forst from the Department of Anesthesiology at Heidelberg University Hospital in Germany commented on the findings, stating, "The results suggest that SeptiCyte RAPID can play a crucial role in clinical settings, helping priority cases for blood culture tests and improving overall efficiency in sepsis management."

The Importance of Rapid Diagnostics in Sepsis

Blood cultures remain foundational in managing sepsis, but they often present challenges, including delayed results and contamination. This innovative study illuminates the pressing need for tools that can guide the use of microbiologic diagnostics, particularly in resource-limited environments such as emergency departments and ICUs.

SeptiCyte RAPID uses advanced molecular technology, specifically reverse transcription polymerase chain reaction (RT-PCR), to evaluate two specific gene expressions—PLAC8 and PLA2G7—in whole blood. This results in a SeptiScore in about 90 minutes, significantly faster than traditional methods.

The implications of this technology are profound. By providing clinicians with actionable insights during the critical early hours of sepsis evaluation, Immunexpress aims to improve patient outcomes and alleviate the economic pressure of sepsis on healthcare systems globally.

About SeptiCyte RAPID and Immunexpress

The SeptiCyte RAPID system is intended to serve alongside clinical evaluation and vital signs, enhancing the differentiation between infection-positive sepsis and non-infectious inflammation. It is designed to be efficient and accessible, running on the Biocartis Idylla™ platform and having received CE Mark approval in Europe as well as FDA clearance in the United States.

Immunexpress is headquartered in Brisbane, Australia, and Seattle, USA, and is dedicated to advancing molecular diagnostics for sepsis management. The company highlights its goal to deliver early, confident decision-making tools to healthcare providers, potentially leading to better patient care and outcomes.

For healthcare professionals interested in integrating SeptiCyte RAPID into their sepsis management protocols, more information can be obtained by contacting the company directly.

Conclusion

This significant publication not only reinforces the role of SeptiCyte RAPID in clinical settings but also emphasizes the urgent need for innovation in sepsis diagnostics. As the healthcare world continues to evolve, technologies that streamline patient assessments and improve outcomes will be paramount in effective sepsis management.